Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Rheumatoid arthritis
3. Epidemiology of RA
4. Normal vs. rheumatoid synovium
5. Rheumatoid synovitis
6. Histological patterns in RA synovitis
7. Pannus formation and joint destruction
8. Disease pathology
9. Histological image of RA joint
10. Pathogenesis of rheumatoid arthritis
11. Cytokine network in rheumatoid arthritis synovia
12. Tumor necrosis factor (TNF)-alpha
13. Key actions attributed to TNF-alpha
14. The key role of TNF-alpha in rheumatoid arthritis
15. Traditional treatment of RA
16. What is the goal of RA therapy?
17. Effect of RA duration on inflammation and function
18. Schematic representation of the course of RA
19. Biologic DMARDs: old and new entries
20. Drugs targeting cytokines
21. TNF antagonists: characteristics
22. Infliximab
23. Infliximab / MTX combination
24. Infliximab and MTX (ATTRACT)
25. Infliximab safety
26. Etanercept
27. TEMPO study objective
28. Study design
29. ACR 20 response: 1 year vs. 2 year
30. ACR 50 response: 1 year vs. 2 year
31. ACR 70 response: 1 year vs. 2 year
32. Inhibition of radiographic progression
33. TEMPO - conclusions
34. Etanercept safety
35. Adalimumab characteristics: fully human mAb
36. ARMADA open-label extension: study design
37. ACR response over time
38. Change in joint count over time
39. Change in HAQ over time
40. DAS28 response over time
41. ARMADA trial: conclusions
42. STAR safety trial: conclusions
43. Evidence for TNF-alpha inhibitors in early RA
44. BeSt: treatment strategies in rheumatoid arthritis
45. Treatment strategies
46. BeSt: Rx score at one year
47. BeSt: % of patients with DAS44 score < 1.6
48. BEST summary
49. Adverse events and TNF antagonists
50. Anakinra
51. Anakinra monotherapy
52. Anakinra / MTX combination
53. Changes total Sharp scores at 24 weeks
54. Anakinra safety
55. Certolizumab (CDP-870)
56. Golimumab (CNTO 148)
57. IL-1 TRAP
58. Cytokine targets
59. Role of IL-6 in rheumatoid arthritis
60. Tocilizumab: humanised anti-IL6 receptor antibody
61. Murine anti-IL-6 monoclonal antibody
62. Blocking of IL-6 signalling by Tocilizumab (MRA)
63. Tocilizumab study
64. Tocilizumab study design
65. ACR responses at week 12
66. Effects of Tocilizumab on CRP and ESR
67. Tocilizumab (phase II trial)
68. CHARISMA - tocilizumab monotherapy
69. CHARISMA - tocilizumab and MTX
70. CHARISMA - long term effects
71. IL-15
72. IL-15 monoclonal antibody (HuMax IL15/AMG 714)
73. IL-12 monoclonal antibody
74. IL-18 binding protein
75. Inhibitors of TACE and caspase-1 as AIDs
76. Chemokines
77. Oral CCR1 antagonist
78. Anti-MCP1 monoclonal antibody (ABM912)
79. B-cell targeting
80. Potential roles of B cells in pathogenesis of RA
81. MabThera: chimaeric anti-CD20 mAb
82. The structure of rituximab
83. Rituximab: mode of action (1)
84. Rituximab: mode of action (2)
85. Rituximab mode of action: B cell depletion by CDC
86. Rituximab mode of action: depletion by ADCC
87. Rituximab mode of action: depletion by apoptosis
88. Case reports and open label study
89. Efficacy of rituximab - study design
90. Efficacy of rituximab - study results
91. Rituximab study - adverse events
92. DANCER study: design
93. DANCER study: ACR response at 24 weeks
94. DANCER study: IV glucocorticoid premedication
95. DANCER study: adverse events
96. Rituximab phase IIB trial - results
97. Rituximab phase IIB trial - conclusions
98. REFLEX study
99. T-cell independent B-cell activation
100. BLyS levels in patients with autoimmune disease
101. Production of BAFF in synoviocytes
102. Inhibiting B-cell survival: lymphostat-B
103. T-cell targeting
104. BMS-188667 (CTLA4-Ig) (Abatacept)
105. Costimulation: activation of T cells and APC
106. Trial evaluating Abatacept
107. Trial evaluating Abatacept - study design
108. ACR response at 3 months
109. Phase 2B study: treatment of RA by abatacept
110. Phase 2B study: methotrexate combination study
111. ACR response at 6 months
112. ACR response at 12 months
113. Abatacept for RA refractory to TNF-alpha inhibition
114. Abatacept for refractory RA - ACR response
115. Abatacept for refractory RA - radiography
116. Safety of Abatacept
117. Abatacept - serious adverse events
118. Osteoclast inhibitors
119. Zoledronic acid
120. RANKL monoclonal antibody (AMG 162)
121. RANKL inhibition with Denosumab
122. Small molecules
123. P38 mitogen-activated protein kinase inhibitors
124. Statins
125. Conclusions (1)
126. Conclusions (2)

Topics Covered

• Characteristics of rheumatoid arthritis (RA)
• Epidemiology
• Disease pathology
• Synovitis
• Cytokine network
• Tumor necrosis factor (TNF)-alpha
• The role of TNF-alpha in rheumatoid arthritis
• Disease-modifying antirheumatic drugs (DMARD)
• TNF antagonists
• Monoclonal antibodies
• Adverse events and TNF antagonists
• Chemokines
• B cell targeting
• T cell targeting
• Costimulation
• The pipeline of new antirheumatic drugs for RA promises to bring new therapeutic possibilities for the future

Links

Series:

• Autoimmunity

Categories:

• Clinical Practice
• Immunology
• Pharmaceutical Sciences

Therapeutic Areas:

• Immunology & Inflammation

Talk Citation

Sarzi-Puttini, P. (2007, October 1). Anti-cytokine therapy in rheumatoid arthritis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/KDCF3168.
Export Citation (RIS)

Publication History

• Published on October 1, 2007
• Archived on October 28, 2018

Financial Disclosures

• Prof. Piercarlo Sarzi-Puttini has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.